



Nuove evidenze sui GLP-1 RA long acting nel diabete di tipo 2

Edoardo Mannucci

Agenzia Diabetologia, AOU Careggi, Firenze

DUALITY OF INTEREST DISCLOSURE

Dr Mannucci has received speaking and/or consulting fees from:


Abbott, AstraZeneca, BMS, Boehringer Ingelheim, Eli Lilly, Janssen, Lifescan, Novartis, Novo Nordisk, Sanofi, Takeda

Dr Mannucci and his research unit received research grants from:

AstraZeneca, BMS, Boehringer Ingelheim, Eli Lilly, Janssen, Novartis, Novo Nordisk

Efficacy of DPP4i and GLP1-RA


Meta-analysis of RCTs as add-on to metformin



Deacon C, Mannucci E, Ahrén B.
Diabetes Obes Metab 2012; 14:762-767.

Exenatide LAR add-on to metformin


The DURATION-2 trial






Exenatide LAR vs glargine

RCT, add-on to Metformin (\pm SU) – DURATION-3



Exenatide LAR vs glargine


RCT, add-on to Metformin (\pm SU) – DURATION-3





Exenatide LAR vs glargine


RCT, add-on to Metformin (\pm SU) – DURATION-3






Exenatide LAR vs glargine

RCT, add-on to Metformin (\pm SU) – DURATION-3




Short- vs. long-acting GLP1-RA

DURATION-1 trial



Exenatide LAR vs bid


RCT in T2DM (DURATION-1)





Exenatide LAR, long-term


Open-label extension of DURATION-1





Exenatide LAR, long-term


Open-label extension of DURATION-1





Exenatide and human β -cells


Effects on palmitate-induced apoptosis





Exenatide LAR, long-term

Open-label extension of DURATION-1





Exenatide LAR, long-term

Open-label extension of DURATION-1

exposure-adjusted event rates of injection-site pruritus (from 51.0 to 1.6 events per 100 patient-years) and injection-site erythema (from 13.7 to 1.2 events per 100 patient-years) also decreased. Injection-site nodules were infrequent during the controlled phase (3.7 events per 100 patient-years) and were not observed in the open-ended extension.